Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Down 7.2% in September

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) was the recipient of a significant drop in short interest during the month of September. As of September 30th, there was short interest totalling 18,000 shares, a drop of 7.2% from the September 15th total of 19,400 shares. Currently, 3.2% of the company’s shares are sold short. Based on an average daily trading volume, of 32,500 shares, the short-interest ratio is presently 0.6 days.

Cadrenal Therapeutics Stock Up 6.2 %

CVKD traded up $0.95 during midday trading on Thursday, reaching $16.30. 100,628 shares of the company were exchanged, compared to its average volume of 24,624. Cadrenal Therapeutics has a one year low of $5.40 and a one year high of $32.55. The firm has a market cap of $260.93 million, a PE ratio of -52.68 and a beta of 1.81. The company’s 50-day simple moving average is $10.48.

Cadrenal Therapeutics (NASDAQ:CVKD) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($33.75) earnings per share for the quarter, beating the consensus estimate of ($285.60) by $251.85. Equities analysts expect that Cadrenal Therapeutics will post -6.72 EPS for the current year.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.